Evidence map›Paper›PMID 24850179›Full record

ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014

PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids.

Filippo Lococo, Alfredo Cesario, Massimiliano Paci, Angelina Filice, Annibale Versari, Cristian Rapicetta, Tommaso Ricchetti, Giorgio Sgarbi, Marco Alifano, Alberto Cavazza and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Impact ofFrontiers in medicine · 2019
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Observational
  9. Value of [EJNMMI research · 2022
    Article
  10. Article
  11. Bronchoscopic diagnosis and treatment of endobronchial carcinoid: case report and review of the literature.European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  12. Review
  13. Review
  14. Article
  15. [Pulmonary carcinoid tumors].Der Radiologe · 2017
    Article
  16. Article
  17. Review
  18. The Diagnosis and Treatment of Bronchopulmonary Carcinoid.Deutsches Arzteblatt international · 2015
    Review
  19. Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Filippo LococoUnit of Thoracic Surgery, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, filippo_lococo@yahoo.it.
Alfredo Cesario
Massimiliano Paci
Angelina Filice
Annibale Versari
Cristian Rapicetta
Tommaso Ricchetti
Giorgio Sgarbi
Marco Alifano
Alberto Cavazza
Giorgio Treglia
Ospedale Santa Maria · ITAzienda Sanitaria Unità Locale di Reggio Emilia · ITDélégation Paris 5 · FRInstitute of Oncology Research · CHIRCCS Ospedale San Raffaele · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary neuroendocrine tumors (pNETs) arise from bronchial mucosal cells known as enterochromaffin cells which are part of the diffuse neuroendocrine system. The pathological spectrum of pNETs ranges from low-/intermediate-grade neoplasms such as bronchial carcinoids (BCs), also known as typical or atypical carcinoids, to high-grade neoplasms as large-cell neuroendocrine carcinoma and small-cell lung cancer. The tumor biology of pNETs still represents a matter of open debate. The distinct features among the different pNETs include not only their pathologic characteristics but also their clinical behavior, epidemiology, treatment, and prognosis. In this sense, a correct pathological identification in the preoperative setting is a key element for planning the best strategy of care in pNETs and especially in BCs. Controversial results have been reported on the diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography or positron emission tomography/computed tomography (F-18-FDG PET or PET/CT) in BCs. On the other hand, there is increasing evidence supporting the use of PET with somatostatin analogues (DOTA-TOC, DOTA-NOC, or DOTA-TATE) labeled with gallium-68 (Ga-68) in pNETs. Herein, we review the pertinent literature aiming to better define the current state of art of PET/CT in the detection and histological differentiation of pNETs with special emphasis on BCs.

Indexed as

Bronchial NeoplasmsCarcinoid TumorFluorodeoxyglucose F18HumansLung NeoplasmsNeuroendocrine TumorsOctreotideOrganometallic CompoundsPositron-Emission TomographySensitivity and SpecificityTomography, X-Ray ComputedFluorodeoxyglucose F18Ga(III)-DOTATOCOctreotideOrganometallic Compounds

Identifiers

PMID24850179
OpenAlexW2076928753

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.